/ Print /

Pharmacy Best Practices

Drug pipeline: Anti-obesity medsObesity and associated comorbidities strain the healthcare system, so why has R&D for new weight loss medications been lackluster?
CMS proposal to address antibiotic resistance: Key takeawaysTo participate in Medicare and Medicaid, hospital and critical access hospitals (CAHs) would need to meet new criteria.
Opinion: Mail-order pharmacy market to grow significantlyShifting patient demographics will create an ideal scenario for the online/mail-order pharmacy market in the next five to ten years.
Risky antibiotic use threatens patientsA new study suggests that patients are willing to use antibiotics without contacting a doctor. Here’s how execs can curb this and avoid antibiotic resistance.
How four health plans are fighting the opioid epidemic
How four health plans are fighting the opioid epidemicFrom new outreach programs to multidisciplinary teams, here are some new strategies health plans are employing to fight the opioid epidemic
Asthma drug pipeline: Prevalence, costs to increase
Asthma drug pipeline: Prevalence, costs to increaseAs asthma prevalence continues to rise in the adult and pediatric populations, U.S. healthcare spending on medications, especially branded inhalers, is expected to increase.
Increased utilization driving pharmacy spend in exchange plansExpress Scripts Exchange Pulse report found that utilization, particularly for traditional meds, was one of the biggest factors driving spending in 2015, accounting for more than half of the exchange plans $99 PMPY increase in spending between 2014 and 2015.
Real-world results determine value-based price for specialty drugsIn an era when adherence to specialty pharmaceuticals is disturbingly low, value-based pricing needs real-world results, not single-arm accelerated trials.
Entresto may prevent death in some heart failure patientsTimely and broad use of Entresto could prevent or postpone more than 28,000 US deaths per year among HFrEF patients, according to research in JAMA Cardiology.
Survey finds stakeholders lack understanding of biosimilarsIt is important to look at how the introduction of biosimilars in the United States may affect your business and your stakeholders and plan for those changes accordingly, according to a new report.